Cargando…

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolerability an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Bo, Qi, Junyuan, Song, Yuqin, Li, Zengjun, Tu, Meifeng, Ping, Lingyan, Liu, Zongliang, Bao, Hanying, Xu, Zusheng, Qiu, Lugui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381505/ https://www.ncbi.nlm.nih.gov/pubmed/34425850 http://dx.doi.org/10.1186/s13045-021-01140-z

Ejemplares similares

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
por: Wang, Tingyu, et al.
Publicado: (2023)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics
por: Zhan, Fenghuang, et al.
Publicado: (2015)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Qiu, Lihua, et al.
Publicado: (2023)

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Sun, Xiuhua, et al.
Publicado: (2023)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

YY1 activates EMI2 and promotes the progression of cholangiocarcinoma through the PI3K/Akt signaling axis
por: Zhou, Shuai, et al.
Publicado: (2021)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform
por: Pei, Yonggang, et al.
Publicado: (2020)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

PI3Kδ过度活化综合征一例
Publicado: (2021)

Genome-wide analysis of YY2 versus YY1 target genes
por: Chen, Li, et al.
Publicado: (2010)

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
por: Liu, Xiaochuan, et al.
Publicado: (2016)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

Retroposition and evolution of the DNA-binding motifs of YY1, YY2 and REX1
por: Kim, Jeong Do, et al.
Publicado: (2007)

Homeostasis Imbalance of YY2 and YY1 Promotes Tumor Growth by Manipulating Ferroptosis
por: Li, Yanjun, et al.
Publicado: (2022)

The hot corona of YY Mensae
por: Güdel, M, et al.
Publicado: (1996)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

TCONS_00012883 promotes proliferation and metastasis via DDX3/YY1/MMP1/PI3K‐AKT axis in colorectal cancer
por: Yang, Peng, et al.
Publicado: (2020)

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma
por: Katsuya, Hiroo, et al.
Publicado: (2018)

Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
por: Zhu, Jingyu, et al.
Publicado: (2019)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

Targeting PI3Kδ: One man’s meat is another man’s poison
por: Prchal-Murphy, Michaela, et al.
Publicado: (2013)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome
por: Donaldson, Stephanie L., et al.
Publicado: (2019)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
por: Wang, Xiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jdeg4bfrcbbks8p4d28c19hkma